CA2601628C — Certain substituted amides, method of making, and method of use thereof
Assigned to Gilead Connecticut Inc · Expires 2014-05-13 · 12y expired
What this patent protects
B-cell development, activiation, signaling and survival are all regulated in part by Bruton's Tyrosine Kinase (Btk). B-cells and Btk have a role in allergic disorders, autoimmune diesase, inflammatory disease, apoptosis and cancer. Inhibition of Btk by at least one chemical entit…
USPTO Abstract
B-cell development, activiation, signaling and survival are all regulated in part by Bruton's Tyrosine Kinase (Btk). B-cells and Btk have a role in allergic disorders, autoimmune diesase, inflammatory disease, apoptosis and cancer. Inhibition of Btk by at least one chemical entity chosen from compounds of Formula 3 (see formula 3) and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures, can be useful in the treatment of diesases that involve Btk. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are also described. Further, methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity and methods for determining the presence of Btk in a sample are provided.
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.